Biliary excretion of platinum in rats after administration of cisplatin and aqua(1,1-bis(aminomethyl)-cyclohexane)sulfatoplatinum(II) (spiroplatin, TNO-6).

@article{vanderVijgh1985BiliaryEO,
  title={Biliary excretion of platinum in rats after administration of cisplatin and aqua(1,1-bis(aminomethyl)-cyclohexane)sulfatoplatinum(II) (spiroplatin, TNO-6).},
  author={Wim J.F. van der Vijgh and Paul C. M. Verbeek and Ina Klein and Herbert Michael Pinedo},
  journal={Cancer letters},
  year={1985},
  volume={28 1},
  pages={
          103-9
        }
}
View on PubMed
doi.org
8 Citations

8 Citations

Broad blocking of MDR efflux pumps by acetylshikonin and acetoxyisovalerylshikonin to generate hypersensitive phenotype of malignant carcinoma cells
TLDR
The results indicated that shik onin derivatives stimulate uptake and reduce efflux of chemotherapeutic agents in the malignant cancer cells, suggesting that chemotherapy in combination with shikonin compounds may be beneficial to cancer cells that overexpress multidrug resistance transporters.
Berries and Cancer
Convolution: a general electrochemical procedure implemented by a universal algorithm
La convolution du courant faradique avec une «fonction de convolution» appropriee, peut generer des donnees de concentration en surface pour une serie de situations electrochimiques. Discussion de 8…
Two novel SNPs in genes involved in immune response and their association with mandibular residual ridge resorption
Pharmacokinetic study of intralesional cisplatin for the treatment of hepatocellular carcinoma
In the current study the authors examined the pharmacokinetics of direct intralesional injection of cisplatin/epinephrine/bovine collagen gel in patients with hepatocellular carcinoma and cirrhosis.
Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of aqua (1,1-bis(aminomethyl)cyclohexane) sulfatoplatinum (II) (spiroplatin) during a phase I trial.
Platinum antitumour agents.
On-line differential pulse polarographic detection of carboplatin in biological samples after chromatographic separation.

References

SHOWING 1-10 OF 11 REFERENCES
Pharmacokinetics of free platinum species following rapid, 3-hr and 24-hr infusions of cis-diamminedichloroplatinum (II) and its therapeutic implications.
Pharmacokinetics of cisplatin regional hepatic infusions.
TLDR
DDP pharmacokinetics in dogs given DDP by infusion and bolus injection in the hepatic artery (H.A.), portal vein (portal V), and peripheral vein (P.V.) is studied.
Preclinical studies on toxicity, antitumour activity and pharmacokinetics of cisplatin and three recently developed derivatives.
Effect of a forced diuresis on the distribution and excretion (via urine and bile) of 195mplatinum when given as 195mplatinum cis-dichlorodiammineplatinum(II).
TLDR
Forced diuresis, if it affords renal protection, does so during the first 90 minutes of urinary excretion, during which time cis-DDP is distributed and retained.
Clinical Experience with 1, 1-Diaminomethylcyclohexane (Sulphato) Platinum (II) (TNO-6)
TLDR
Although nephrotoxicity is generally considered as the major dose limiting toxicity, methods to overcome this toxicity have created the possibility to administer multiple courses of the drug, with prolonged treatment other toxicities may become dose-limiting.
Pharmacokinetics of free and total platinum species after short-term infusion of cisplatin.
TLDR
The binding of platinum to both plasma and proteins and rbcs in vitro (using patients' own blood) was slow, biphasic, and irreversible.
Molecular weight as a factor in the excretion of monoquaternary ammonium cations in the bile of the rat, rabbit and guinea pig.
TLDR
The results suggest that the threshold molecular weight for the appreciable biliary excretion of monoquaternary cations is different from that for anions (Millburn et al., 1967a) and studies with six cations in guinea pigs and rabbits suggest that this value applies also to these species.
Biliary Excretion, Renal Handling and Red Cell Uptake of Cisplatin and CBDCA in Animals
TLDR
Cis-diammine (1,1-cyclobutanedicarboxylato)platinum II (CBDCA, JM8) as a potential alternative to cisplatin in cancer chemotherapy and phase II and III studies are currently in progress.
New platinum complexes in clinical trials.
Biliary excretion of drugs and other xenobiotics.
  • W. G. Levine
  • Medicine, Biology
    Annual review of pharmacology and toxicology
  • 1978
TLDR
The clinical significance of this work is still somewhat dependent upon results obtained from lower animals, although studies occasionally appear on patients who have temporary bile drainage subsequent to surgery, and it is important that efforts persist in obtaining data in humans since extrapolation fromLower animals in the area of drug disposition is often precarious.
...
...